Grifols has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols Egypt for Plasma Derivatives (GEPD), a project by the Catalan multinational specializing in plasma derivatives in partnership with the Egyptian government. The authority responsible for the scientific evaluation, supervision, and safety control of medicines in the European Union (EU) confirmed that the entire Grifols Egypt plasma platform "operates under the most demanding European standards of quality, safety, and regulatory control," the company explains. Thanks to this certification, Egypt becomes the first country in Africa and the Middle East to operate a fully integrated plasma collection and processing system "that meets the strictest international standards throughout the entire cycle, from the medical evaluation of donors and the donation process to the analysis of the medicines" and the plasma processing. This also facilitates the country's progress toward exporting surplus medicines derived from Egyptian plasma to other markets, particularly in Europe, including Spain.